Sponsor Overview
Explore verified public information about MEDRx USA., Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria MEDRx USA, Inc. (MEDRx) is a clinical-stage pharmaceutical company that focuses on research and development of proprietary investigational products. Investigational drug products generally can only be provided to subjects enrolled in clinical studies as such products are not approved by the U.S. Food and Drug Administration (“FDA”) as safe and effective for their intended use. While investigational product manufacturers may provide investigational products to certain patients under FDA’s Expanded Access Program (sometimes called “compassionate use”), if the patients meet certain criteria required by FDA law and regulation, at this time, MEDRx will not offer expanded access to investigational products outside of enrollment in clinical trials and is currently not accepting expanded access requests. If you have questions or need more information about our programs, please feel free to contact MEDRx at info@medrxusa.com . MEDRx endeavors to respond within five business days. In line with the 21st Century Cures Act, MEDRx may revise this policy at any time.
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.